(Date:11/23/2009)...ewswire/-InimexPharmaceuticals,Inc.announcedtodayt...tandCEO. ,, Abramsbringsmorethan25yearsofdrugdi...ventorofthenuclearmedicineimagingagent,Cardiolite,...wasManager,BiomedicalResearchWorldwide.In1996,Abra...esidentandCEOfrom1996to2006.AnorMEDdiscoveredandde...
(Date:11/20/2009)...untries have an opportunity to take the lead in tw...e University of Valencia (UV), working together wi...tive fabric of the Spanish biotechnology industry....ectors have more clout than those in English-speak...d and plants has been overlooked by the leading co...
(Date:11/20/2009)...20 Cell Therapeutics, In...at the Ninth Circuit Court of Appeals reversed a U... be allowed to pursue all of its claims against Th...t Court for trial. CTI filed a complaint against ...ment consultant for CTI,s product TRISENOX, in 200...
(Date:11/19/2009)...PRNewswire-FirstCall/ -- Omeros Corporation (Nasda...ults for the third quarter ended September 30, 200...Omeros reported a net loss of $3.9 million, or $1....llion, or $2.54 per share, for the same period in ..., the Company reported a net loss of $15.5 million...
Breaking Biology Technology:Inimex Announces Appointment of New CEO 2Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8...n throughout bioscience industry ... 14 A new report ranks Ohio best in,the Midwest f...on and,business growth, according to the Ohio Busi...rganization that markets the state for capital,inv...Cleveland, Ohio-based,bioscience incubator, shows ...
... Institute,(KGI) today announced the election of t...ne M. Burzik, chief executive officer of Kinetic C...resident for manufacturing at,Gilead Sciences; and...Burling LLP. KGI,s board consists of leaders in b...e formation of KGI since its founding in 1997. Wit...
...gust 16 /PRNewswire-FirstCall/,-- Santhera Pharmac...y,pharmaceutical company with a focus on neuromusc...imited (TSE:4502, "Takeda"), jointly announced,tod...ccepted the filing of,the Marketing Authorization ...-MC17 (INN: idebenone, originally developed by Tak...
Other Biology Technology:Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry 2KGI Elects Three New Members to Board of Trustees 2European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 2European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 3European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 4European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 5European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 6Normal Porcine Serum from Equitech-Bio
Anti-Foam Reagent from Promega
Viral CCI, Unconjugated, Fc Chimera from R&D Systems
GENOMIPHI V2 DNA AMP KIT 25RXN from GE Healthcare, formerly Amersham Biosciences
Biology Products: